Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 3/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 6/20 | 0.40 |
| ▸ | ERCC5 | P28715 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxaloacetate SCHEMBL6310306 | 1.00 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL4298763 | 0.96 | LDHA (0.57) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL8464 | 0.96 | — | — | |
| Oxaloacetate SCHEMBL898612 | 0.96 | LDHA (0.57) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL25210523 | 0.93 | — | — | |
| Oxaloacetate SCHEMBL11328361 | 0.93 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL9782818 | 0.93 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL8638879 | 0.93 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL9994505 | 0.93 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 | |
| Oxaloacetate SCHEMBL6545252 | 0.93 | LDHA (0.53) | LDHASRROR51E2EGLN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Ivan Aleksandrovich Starikov | 2019-04-25 | — | — | US | disclosed |
| EP-3473098-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | Gorbunov, Sergei Valeryevich (RU) | 2019-04-24 | — | — | EP | disclosed |
| CN-105505892-B | The production method of 2,4- dihydroxy butyric acid | 安迪苏法国联合股份有限公司 | 2019-03-26 | — | — | CN | disclosed |
| CN-104254612-B | A kind of production method of 2,4- dihydroxy butyric acid | 安迪苏法国联合股份有限公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-105505892-A | Method for producing 2,4-dihydroxybutyric acid | ADISSEO FRANCE SAS | 2016-04-20 | — | — | CN | disclosed |
| CN-105497014-A | Compositions and methods for improving mitochondrial functions | AMAZENTIS SA | 2016-04-20 | — | — | CN | disclosed |
| CN-103442594-B | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS S.A. (CH) | 2016-02-17 | — | — | CN | disclosed |
| CN-103270155-B | Method for producing 2, 4-dihydroxybutyric acid | ADISSEO FRANCE S.A.S. (FR) | 2016-02-10 | — | — | CN | disclosed |
| CN-104254612-A | A method of production of 2,4-dihydroxybutyric acid | ADISSEO FRANCE SAS | 2014-12-31 | — | — | CN | disclosed |
| CN-103270155-A | Method for producing 2, 4-dihydroxybutyric acid | ADISSEO FRANCE SAS | 2013-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119193-A1 | COMPOSITION FOR REGULATING PLANT GROWTH, METHOD FOR TREATING PLANTS THEREWITH, AND ACTIVE INGREDIENT THEREOF | OGDH, GOT1, OAT | LDHA 476/4885SRR 727/4885OR51E2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.